Psoriasis Vulgaris
Conditions
Keywords
Topical, Real-world, Local standard of care, Non-interventional, Calcipotriol
Brief summary
Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).
Detailed description
This multinational study aims to describe current treatment patterns and outcomes in the diversity of the real life setting: local differences in access to drugs and current treatment practices, and regional cultural differences, covering adult patients of all backgrounds, sex, socio-economic standing, health background, comorbidity and co-medication. A total of around 400 real-life prescribers in 3-8 countries are expected to participate over the years, with each country contributing data to the study for around 2 years, starting data collection within the first year after local market introduction of Enstilar®. The real-life prescribing and utilization patterns of topical prescription products approved for treatment of psoriasis vulgaris in the individual participating countries will be mapped and performance of the products in real life will be investigated based primarily on baseline data from investigators and patient reported data contributed by the individual patient for 1 year. Patients are expected to enter data on their electronic device at baseline and at times of treatment changes and other key events, and investigators are expected to contribute data after each contact with the patient. Patients will be approached for informed consent to participate in the study after their individual treatment plan has been decided. The study aims to include two patients on other topical treatment for every patient planned to receive Enstilar® in order to ensure a sufficient sample of Enstilar® treated patients to capture the diversity of real-life prescription patterns in patients not on Enstilar®, and to allow for sufficiently powered comparisons between Enstilar® and other real-world treatment strategies. A systematic approach will be used to select eligible patients to be approached for study participation in order to minimize selection bias and control seasonal variations.
Interventions
DRUGEnstilar® aerosol foam
Treatment according to local labelling
DRUGOther topical
Treatment according to local practise
Sponsors
LEO Pharma
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult age * Psoriasis vulgaris * Plaques on the body (trunk and/or extremities) of at least mild severity at time of inclusion * Decision to prescribe a topical psoriasis treatment for body use where the prescription is NOT a routine renewal of the prescription of an ongoing therapy * Signed and dated informed consent * Willingness and ability to enter personal disease and treatment information onto a secure webpage during the one year individual study period, using their existing access to a PC or electronic device and a personal access code.
Exclusion criteria
* Participation in the active treatment phase of a clinical trial * Previous enrollment in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PaGA | 4 weeks | Patient reported Global Assessment |
| Itch | 1 week | Itch dimension of Psoriasis Symptom Inventory (PSI) questionnaire |
| Switch | 1 year | Time to switch of topical treatment strategy |
| Flare-up | 1 year | Time to first flare-up after initial treatment completion |
Countries
Canada, Sweden, United Kingdom
Outcome results
None listed